Lesson
Recognize a Multisystem Disease
SLE is not one rash, one antibody, or one laboratory result. It is a heterogeneous autoimmune disease whose active manifestations, dangerous mimics, and accumulated damage must be mapped across the whole patient.
- Multisystem phenotype
- ANA entry criterion
- Weighted domains
- Flare versus infection
- Drug-induced lupus
Connect skin, joints, blood, kidney, nervous system, lungs, heart, and vessels.
Use serology, complement, urine, imaging, and examination to strengthen clinical judgment.
Evaluate infection, toxicity, thrombosis, malignancy, and fixed damage beside the flare.
Map the phenotype
Inflammatory skin, joint, blood, kidney, cardiopulmonary, vascular, and nervous-system findings can appear together or over time. New edema, neurologic change, bleeding, dyspnea, chest pain, or hemodynamic instability changes urgency.
Use criteria without surrendering judgment
The 2019 EULAR/ACR research classification system requires ANA at least 1:80 on HEp-2 cells, or an equivalent positive test, at least once. After entry, classification requires at least one clinical criterion and at least ten weighted points. Count only the highest-scoring item in each domain and exclude findings with a more likely explanation. Findings need not occur simultaneously. This system supports consistent research classification; neither ANA positivity nor a score replaces clinical diagnosis, and persistently ANA-negative patients cannot be classified by this system even though rare clinical SLE exists.
Run flare and mimic in parallel
Fever, fatigue, cytopenias, organ dysfunction, and inflammatory markers may reflect active SLE, infection, medication toxicity, thrombosis, malignancy, or overlap disease. Unstable patients require immediate treatment of dangerous possibilities while the cause is clarified.
Recognize a drug relationship
Associated medicines include procainamide, hydralazine, isoniazid, minocycline, quinidine, methyldopa, methimazole, propylthiouracil, and TNF inhibitors such as adalimumab. Oral terbinafine can precipitate or exacerbate cutaneous or systemic lupus. These associations do not imply equal incidence or identical syndromes. Review exposure, timing, phenotype, autoantibodies, and improvement after withdrawal; an isolated positive ANA is not proof of symptomatic drug-induced lupus.
Do not minimize drug-related organ disease
A suspected drug cause does not make kidney, lung, or neurologic findings safe to observe. Hydralazine-associated lupus can include glomerulonephritis, and antithyroid drugs can cause serious vasculitic syndromes. Coordinate withdrawal or substitution with the treating team while urgently assessing organ injury and alternative causes. Clinical improvement after withdrawal supports attribution, but neither immediate recovery nor normalization of every antibody is required before the possibility is taken seriously.
Quick check
Checking for saved practice…
Lesson
Trace the Immune Architecture
SLE emerges from interacting susceptibility, cellular debris, nucleic-acid sensing, type I interferon, autoreactive B cells, autoantibodies, complement, and tissue-specific injury. That network explains why no single marker or target describes every patient.
- Immune tolerance
- Nucleic-acid sensing
- Type I interferon
- BLyS
- Immune complexes
Innate sensing amplifies type I interferon programs and inflammatory gene expression.
Autoreactive B cells persist, differentiate, and contribute to autoantibody production.
Complement activation and local inflammation translate systemic autoimmunity into organ damage.
Lose tolerance
Genetic, epigenetic, hormonal, infectious, and environmental factors can alter immune tolerance and clearance of apoptotic material. Exposed nuclear antigens then become part of a self-sustaining innate and adaptive immune response.
Amplify interferon
Nucleic-acid sensing can activate type I interferon programs and inflammatory gene expression. Anifrolumab binds IFNAR1, inhibits type I interferon signaling, and reduces available receptor at the cell surface.
Sustain autoreactive B cells
BLyS supports B-cell survival and differentiation. Belimumab binds soluble BLyS and reduces survival signaling, while anti-CD20 therapies deplete a B-cell lineage more directly. These are related but distinct strategies.
Deposit immune complexes
Autoantibody-containing immune complexes can activate complement and inflame tissue. Complement and anti-dsDNA trends may support assessment, but organ findings, urine, examination, and function determine whether treatment should change.
Quick check
Checking for saved practice…
Lesson
Treat Activity Before It Becomes Damage
Current care aims for remission or low disease activity, early control of organ-threatening inflammation, reduced glucocorticoid exposure, and deliberate prevention of irreversible disease and treatment damage.
- Activity
- Damage
- Organ priority
- Prednisone taper
- Escalation
Name the organ, severity, dangerous alternative, and immediate treatment target.
Use early steroid-sparing therapy and taper glucocorticoids as control becomes durable.
Do not intensify immunosuppression for fixed injury or a noninflammatory symptom pattern.
Prioritize irreversible risk
When several organs are active, therapy should cover the full flare but prioritize the manifestation most likely to threaten life or permanent function. Severe neurologic, renal, hematologic, vasculitic, pulmonary, and cardiac disease can require urgent combination therapy.
Measure activity and damage separately
Assess disease activity regularly, especially when clinical status or SLE-directed therapy changes. Assess accumulated damage at least annually. Chronic pain, avascular necrosis, scarring, neuropathy, or fatigue may not improve with more immunosuppression.
Use glucocorticoids as a bridge
For organ-threatening flares, pulse methylprednisolone may precede an oral taper. Once stable and controlled, current ACR guidance strongly recommends reaching prednisone 5 mg daily or less, ideally zero, within six months when feasible. At low doses, taper slowly and assess symptoms for adrenal insufficiency or glucocorticoid withdrawal as well as lupus activity; fatigue during taper does not by itself prove inflammatory relapse.
Escalate refractory inflammation
Confirm diagnosis, actual medication exposure, dose, duration, access, and competing explanations. If active disease remains refractory, change or add an organ-appropriate conventional or biologic immunosuppressive therapy rather than preserving an ineffective plan.
Quick check
Checking for saved practice…
Lesson
Make Hydroxychloroquine a Complete Safety System
Hydroxychloroquine is foundation therapy for most people with SLE, including during sustained remission. Its value depends on durable access, correct exposure, eye surveillance, and recognition of cardiac, metabolic, neuromuscular, and skin toxicity.
- Routine therapy
- Long-term continuation
- 5 mg/kg
- Retinal screening
- Systemic toxicity
Keep the long-term average at 5 mg/kg per day or less unless a deliberate exception is justified.
Match eye follow-up to dose, duration, kidney function, tamoxifen, and macular risk.
Investigate new conduction disease, cardiomyopathy, hypoglycemia, weakness, rash, or blood abnormalities.
Use it routinely
The 2025 ACR guideline strongly recommends hydroxychloroquine unless contraindicated and conditionally recommends indefinite continuation even during sustained remission. Do not remove the foundation automatically because symptoms are quiet.
Calculate long-term exposure
Use actual body weight and target a long-term average daily dose of 5 mg/kg or less. A 68 kg adult has a 340 mg average daily target ceiling for long-term treatment. ACR 2025 permits selected short courses of 5 to 6.5 mg/kg/day for initiation or incomplete disease control; these require a deliberate specialist benefit-risk decision, not routine upward rounding of the maintenance dose. Because tablets are fixed strengths, clinicians may prescribe a weekly schedule that preserves the average. AAO 2025 also advises keeping the daily dose below 400 mg in severe obesity; actual-weight calculation is not permission to escalate indefinitely.
Protect vision
AAO 2025 recommends baseline fundus examination, optical coherence tomography (OCT), and fundus autofluorescence (FAF) soon after starting. Annual OCT and wide-pattern FAF may be deferred during the first five years only when significant risk factors are absent. Kidney disease, tamoxifen, older age at initiation, dose, and duration influence risk. Examine both parafoveal and pericentral regions; visual fields or multifocal electroretinography can confirm suspected changes. Severe toxicity may progress after stopping, so coordinate prompt ophthalmic and prescribing review.
Look beyond the retina
Cardiomyopathy, conduction disease, QT prolongation, hypoglycemia, neuromyopathy, severe skin reactions, and blood disorders are clinically important. New syncope, block, proximal weakness, severe rash, or unexplained hypoglycemia deserves urgent review. New depression, suicidal thoughts, or other major mood changes also require prompt evaluation; neuropsychiatric reactions can occur without a psychiatric history. Renal phospholipidosis is a rare drug-related cause of proteinuria or declining function that may mimic nephritis; the label calls for discontinuation when renal toxicity is suspected or demonstrated by biopsy.
Quick check
Checking for saved practice…
Lesson
Match Therapy to the Active Organ
Nonrenal SLE spans cutaneous, musculoskeletal, serosal, hematologic, neurologic, cardiac, pulmonary, and vascular disease. The therapy must fit the organ, severity, exclusions, and speed of injury.
- Cutaneous lupus
- Inflammatory arthritis
- Serositis
- Cytopenias
- Neurocardiopulmonary disease
Build from photoprotection and hydroxychloroquine toward durable steroid-sparing control.
Grade urgency, exclude competing causes, and match treatment to bleeding or physiologic risk.
Treat inflammatory emergencies in combination while evaluating infection, ischemia, embolism, and damage.
Treat skin with a ladder
Photoprotection, hydroxychloroquine, and site-appropriate topical glucocorticoid or calcineurin inhibitor form the base. Persistent moderate or severe disease can justify methotrexate, a mycophenolic acid analog, anifrolumab, or belimumab rather than repeated systemic-steroid bursts.
Make photoprotection specific to lupus
Use broad-spectrum UVA/UVB protection together with shade, protective clothing, adequate application, and reapplication. The 2025 ACR lupus guideline explanatory text suggests SPF at least 70 for organic-filter sunscreens and at least 50 for mineral-filter sunscreens. These lupus-specific targets go beyond the general-population SPF 30 minimum taught in the sunscreen module; higher SPF does not permit longer exposure or replace reapplication. Choose a tolerable finished product and obtain dermatology input for significant photosensitive disease.
Distinguish mild persistent skin disease
For mild skin-predominant lupus persisting despite hydroxychloroquine and topical therapy, ACR conditionally favors adding quinacrine or switching to chloroquine before systemic immunosuppression. Access to quinacrine and individual safety matter. Chloroquine has greater retinal risk than hydroxychloroquine; the ACR explanatory text suggests eye monitoring every four to six months, explicitly more frequent than the cited AAO annual schedule. This is a specialist-directed change, not an interchangeable antimalarial refill.
Recognize skin-subtype exceptions
Mild persistent bullous lupus can favor dapsone after topical and antimalarial therapy; assess G6PD and monitor for hemolysis and methemoglobinemia. Moderate or severe refractory bullous disease may require conventional immunosuppression or anti-CD20 therapy. Persistent chilblain lupus can favor pentoxifylline, a PDE5 inhibitor, or a calcium-channel blocker before immunosuppression. Mild skin-limited leukocytoclastic vasculitis can favor dapsone or colchicine, while extensive or systemic disease needs a different level of treatment.
Escalate skin therapy without hiding uncertainty
Lenalidomide is a conditional last-resort option for moderate or severe cutaneous disease refractory to topical, antimalarial, and conventional or biologic treatment. It requires REMS participation and careful teratogenicity and thrombosis safeguards. Alopecia requires assessment of its cause, and lupus panniculitis involves subcutaneous fat that topical corticosteroids do not adequately reach. Dermatology review and, when indicated, biopsy help avoid treating every lupus-associated skin finding alike.
Build durable joint and serosal control
Short NSAID or limited glucocorticoid use may bridge inflammatory arthritis. For persistent arthritis on hydroxychloroquine, ACR 2025 conditionally favors initial methotrexate, azathioprine, or a mycophenolic acid analog, with a low threshold to add or switch to belimumab or anifrolumab for inadequate response. Pleuropericarditis requires exclusion of infection, ischemia, embolism, and tamponade before an SLE label is accepted. ACR conditionally favors an NSAID, colchicine, or both initially, with a low threshold for glucocorticoids and steroid-sparing escalation for persistent or recurrent disease. NSAID selection must account for renal, gastrointestinal, and cardiovascular risk.
Grade hematologic urgency
Asymptomatic neutropenia or lymphopenia attributed to SLE without other activity generally does not justify starting immunosuppression. This differs from chronic asymptomatic platelets below 30,000/mcL, for which ACR conditionally favors glucocorticoid plus another suitable therapy over observation or glucocorticoid alone. Active bleeding from severe thrombocytopenia or unstable autoimmune hemolysis can require glucocorticoid plus IVIG and or anti-CD20 therapy rather than observation.
Treat inflammatory emergencies in combination
Myelitis, optic neuritis, acute confusional state, vasculitis, diffuse alveolar hemorrhage, myocarditis, and selected seizures need immediate specialist evaluation. Symptom control alone does not treat the inflammatory driver. ACR conditionally favors IV cyclophosphamide with glucocorticoids for active lupus myelitis. In contrast, isolated cognitive dysfunction confirmed by neuropsychological testing is not an indication to add immunosuppression to cognitive therapy. For life-threatening lupus vasculitis, plasma exchange and/or IVIG may supplement glucocorticoid and immunosuppressive treatment. Acute lupus myocarditis requires both inflammatory treatment and appropriate heart-failure care. Libman-Sacks endocarditis requires cardiology assessment of embolic risk and anticoagulation and/or immunosuppression; do not confuse sterile vegetations with an exclusion of infective endocarditis without evaluation.
Quick check
Checking for saved practice…
Lesson
Choose Conventional Immunosuppression by Organ and Risk
Methotrexate, azathioprine, mycophenolic acid analogs, calcineurin inhibitors, and cyclophosphamide are not interchangeable. Their role follows organ involvement, severity, prior response, toxicity, interactions, and reproductive plans.
- Methotrexate
- Azathioprine
- Mycophenolate
- Calcineurin inhibitors
- Cyclophosphamide
Match the active organ, monitoring burden, interactions, and reproductive plan.
Use organ-specific evidence and follow blood, kidney, pressure, infection, and exposure.
Balance urgent disease control against marrow, bladder, malignancy, gonadal, and cumulative toxicity.
Fit the lower-risk organ
Methotrexate can support inflammatory arthritis and selected skin disease. Azathioprine can serve several nonrenal and maintenance roles and may fit pregnancy planning better than methotrexate or mycophenolate, but blood, liver, thiopurine, and interaction risks remain.
Make thiopurine monitoring explicit
Assess TPMT and NUDT15 susceptibility before azathioprine using available testing and the prescribing protocol. Testing does not replace CBC monitoring. The azathioprine label specifies CBC with platelets weekly during month one, twice monthly during months two and three, then monthly or more often after dose or therapy changes. Recent transfusion can invalidate red-cell TPMT phenotyping. Liver tests and clinical toxicity assessment remain part of follow-up.
Use mycophenolate deliberately
Mycophenolate suppresses lymphocyte purine synthesis and is central to many nephritis and organ-threatening strategies. Monitor blood counts, infection, gastrointestinal effects, organ function, interactions, and reproductive risk.
Reserve cyclophosphamide for the right severity
Cyclophosphamide can be life-saving in selected severe renal, neurologic, vasculitic, or cardiopulmonary disease. Infection, marrow, bladder, malignancy, cumulative-dose, and gonadal toxicity require protocolized prevention and monitoring.
Reconcile every transition
Febuxostat is contraindicated with azathioprine because xanthine oxidase inhibition can cause severe thiopurine toxicity. If allopurinol is deliberately co-prescribed, azathioprine labeling calls for reduction to approximately one-third to one-quarter of its usual dose with close blood-count monitoring; individual enzyme activity may require further reduction or another therapy. Kidney function changes mycophenolate and calcineurin-inhibitor context. Pregnancy plans can require a disease-stable transition long before conception.
Quick check
Checking for saved practice…
Lesson
Use Biologic Targets Without Blurring Their Boundaries
Belimumab, anifrolumab, and CD20-directed therapies act at different points in B-cell and interferon biology. Current indications, age limits, organ exclusions, routes, and safety plans determine how each fits.
- Belimumab
- BLyS
- Anifrolumab
- IFNAR1
- Anti-CD20
Reduce soluble B-cell survival signaling within its labeled age, route, and organ boundaries.
Block type I interferon signaling for appropriate adult nonrenal disease.
Separate guideline use from current FDA indications and preserve infusion, infection, and hepatitis planning.
Inhibit BLyS
Belimumab is labeled with standard therapy for active SLE and active lupus nephritis in patients five years and older. Adult IV dosing is 10 mg/kg on days 0, 14, and 28, then every 28 days. Adult subcutaneous nonrenal SLE dosing is 200 mg weekly. For adult active nephritis, use 400 mg weekly for four doses, then 200 mg weekly; each 400 mg dose requires two separate 200 mg injections. Pediatric subcutaneous schedules depend on weight and indication and use the autoinjector, not the prefilled syringe.
Use the pediatric belimumab schedule
For ages five and older, SC treatment uses the autoinjector. Nonrenal SLE at 15 to less than 40 kg uses 200 mg every two weeks; at 40 kg or more, 200 mg weekly. Active nephritis at 15 to less than 40 kg uses 200 mg weekly for four doses, then every two weeks; at 40 kg or more, 400 mg weekly for four doses, then 200 mg weekly. Patients younger than ten require administration by a trained caregiver or healthcare professional. IV dosing remains 10 mg/kg for either indication from age five, infused over one hour after reconstitution and dilution, never an IV push.
Build belimumab-specific precautions
Assess depression and suicide risk before therapy and during follow-up. Suspected PML requires suspension of immunosuppression while evaluated. Serious hypersensitivity requires immediate discontinuation; suspected SJS/TEN requires stopping, specialist assessment, and permanent avoidance if attributed to belimumab. Avoid live vaccines for 30 days before and during treatment. Severe active CNS lupus is outside the recommended population. New infection may require interruption; combining with rituximab has increased serious infection and systemic-reaction risk.
Interpret subgroup evidence honestly
The current belimumab label retains mixed results in Black participants: early exploratory IV subgroups favored placebo, a later dedicated trial numerically favored belimumab without statistical significance, and the SC subgroup numerically favored belimumab. These findings support discussing uncertainty; they do not establish that an individual patient will respond poorly because of race, nor justify promising equal efficacy from those subgroup data alone.
Block IFNAR1
Anifrolumab is labeled for adults with moderate to severe SLE receiving standard therapy. The April 2026 label offers IV 300 mg infused over 30 minutes every four weeks or subcutaneous 120 mg weekly. It is not recommended for severe active lupus nephritis or severe active CNS lupus.
Plan anifrolumab administration and transitions
For SC dosing, allow the syringe or pen to reach room temperature for 60 minutes. Use the thigh or abdomen, avoiding the area within 5 cm of the navel; a caregiver or healthcare professional may use the upper arm. Rotate sites and avoid damaged skin. Give a missed SC dose when remembered, then maintain at least three days between injections. A missed IV dose is given promptly, with at least 14 days between infusions. For IV-to-SC switching, the first injection is approximately two weeks after the infusion; for SC-to-IV, the first infusion is approximately three to four weeks after the injection. Confirm the prescribed transition rather than applying another biologic's schedule.
Deplete CD20-positive cells
Rituximab is used in selected guideline scenarios but does not have a general SLE indication. Obinutuzumab has an adult active lupus nephritis indication with standard therapy. Its IV dose is 1,000 mg initially and at weeks 2, 24, and 26, then every six months; dose five is six months after dose four. Do not substitute its oncology schedules. Both require infusion and hepatitis B planning.
Prepare for obinutuzumab safely
For lupus nephritis, the label specifies 80 mg IV methylprednisolone completed 30 to 60 minutes before infusion, plus acetaminophen 650 to 1,000 mg and an antihistamine such as diphenhydramine 50 mg. Starting with dose six, IV corticosteroid premedication is reserved for patients with a reaction during the preceding infusion. Continue the other indicated premedications. First infusion starts at 50 mg/hour, increasing by 50 mg/hour every 30 minutes to at most 400 mg/hour. Later standard infusions start at 100 mg/hour and increase by 100 mg/hour every 30 minutes to the same maximum. A shorter infusion from dose two onward requires the label's prior-reaction eligibility and continued premedication.
Separate reaction, infection, and reactivation
Check HBsAg and anti-HBc before obinutuzumab; prior HBV, including resolved infection, needs specialist prevention and monitoring. New neurologic findings require evaluation for PML. Do not administer during active infection. Severe or prolonged neutropenia can require delay, frequent counts, and antimicrobial prophylaxis. Suspected hypersensitivity or serum sickness requires permanent discontinuation, unlike some infusion reactions that permit a slower restart. Avoid live vaccines until B-cell recovery. Tumor-lysis prophylaxis from oncology protocols should not be imported automatically into lupus nephritis, where the label does not identify tumor lysis as a risk.
Preserve one rationale
Avoid routine dual-biologic therapy. Screen and respond to infection, update indicated vaccines, review hypersensitivity and malignancy context, and document the exact organ target and expected response.
Quick check
Checking for saved practice…
Lesson
Detect and Treat Lupus Nephritis Early
Kidney injury can be clinically quiet until proteinuria, active sediment, hypertension, or declining function becomes visible. Contemporary care screens earlier, biopsies at a lower threshold, and often combines therapies from the start.
- Proteinuria screening
- Kidney biopsy
- Class III and IV
- Class V
- Triple therapy
Look even when symptoms are quiet and accelerate evaluation during extra-renal activity.
Distinguish active, chronic, proliferative, and membranous injury before choosing a regimen.
Use proteinuria, kidney function, pressure, urine sediment, exposure, and toxicity to judge response.
Screen before symptoms
In SLE without known kidney disease, quantify urine protein at least every six to twelve months and during extra-renal flares. New urine abnormalities, hypertension, edema, or kidney dysfunction require faster evaluation.
Use biopsy to direct treatment
Current ACR guidance conditionally recommends biopsy when urine protein exceeds 0.5 g/g and or kidney function is impaired without another explanation. Histology separates active, chronic, proliferative, and membranous patterns that require different strategies. Suspected active nephritis warrants prompt specialist-directed glucocorticoids while awaiting biopsy and histopathology; do not delay urgent inflammatory treatment solely for the report.
Build contemporary combination therapy
For active class III or IV nephritis, current options pair glucocorticoid with mycophenolate plus belimumab, mycophenolate plus a calcineurin inhibitor, or low-dose cyclophosphamide plus belimumab. Pure class V disease with proteinuria at least 1 g/g favors glucocorticoid, mycophenolate, and calcineurin inhibition.
Choose the regimen and steroid course deliberately
ACR conditionally favors mycophenolic acid analog regimens over cyclophosphamide regimens. In class III/IV disease, proteinuria at least 3 g/g favors a mycophenolate-plus-CNI combination; moderate to severe active extrarenal manifestations favor a belimumab-containing combination. Low eGFR, uncontrolled blood pressure, or substantial chronic biopsy damage can instead favor belimumab over a CNI because of nephrotoxicity and hypertension risk. The Euro-Lupus low-dose cyclophosphamide course is 500 mg IV every two weeks for six doses, followed by substitution with a mycophenolic acid analog. For active class III/IV disease, the ACR MMF target is 2 to 3 g/day, adjusted for tolerability and clinical context; it is not a tablet-for-tablet substitution with enteric-coated mycophenolic acid. The adult glucocorticoid framework is IV methylprednisolone 250 to 1,000 mg daily for one to three days, then oral prednisone-equivalent at most 0.5 mg/kg/day, capped at 40 mg/day, tapered to at most 5 mg/day by six months. Pediatric dosing requires adjustment rather than automatic use of adult pulse doses.
Define renal response numerically
ACR defines complete response as proteinuria below 0.5 g/g with kidney function stable or improved and at least 80% of baseline. Partial response requires at least a 50% proteinuria reduction to below 3 g/g, also with kidney function at least 80% of baseline. Assess these targets over six to twelve months; complete response may take longer. For example, 4.0 to 1.8 g/g is a 55% fall: with stable kidney function it meets partial, not complete, response. These consensus definitions do not substitute for the full trajectory or imply histologic remission.
Distinguish response from deterioration
Do not wait six months when kidney function is falling rapidly or proteinuria is rising: reassess and change therapy earlier, even within three months. A patient improving on triple therapy with partial response may continue that regimen under close review; partial response after dual therapy conditionally favors escalation to triple therapy. Failure of two appropriate treatment courses warrants specialist reassessment for refractory disease, including activity versus irreversible damage.
Recognize other biopsy patterns
Pure class V disease below 1 g/g proteinuria is not automatically untreated: ACR conditionally favors glucocorticoid and/or MPAA, azathioprine, or a CNI, with very limited evidence. Class II disease, podocytopathy, and thrombotic microangiopathy need their own nephrology assessment. A thrombotic biopsy pattern can reflect APS, TTP, complement-mediated disease, or another cause; do not apply the proliferative-nephritis regimen indiscriminately.
Interpret incomplete response
First verify dose, actual exposure, access, and competing kidney diagnoses. If at least a partial response has not occurred by six to twelve months, ACR conditionally favors escalation: dual therapy to triple therapy, or initial triple therapy to an alternative combination or selected anti-CD20 treatment. Repeat biopsy can be appropriate for suspected relapse or ongoing renal abnormalities after at least six months of adequate treatment. After complete response, the guideline recommends at least three to five years of total immunosuppressive treatment; this is not permission to stop when proteinuria first improves.
Continue the regimen that achieved response
After complete response to triple therapy, ACR conditionally favors continuing that immunosuppressive regimen. After complete response to dual glucocorticoid plus cyclophosphamide or MPAA therapy, ongoing MPAA is conditionally preferred over azathioprine. Pregnancy plans, intolerance, access, and individual risk can change this choice; complete response is not an instruction to withdraw all treatment.
Preserve kidney health beyond immune control
With elevated proteinuria, consider renin-angiotensin system inhibition when appropriate, while accounting for potassium, kidney function, and pregnancy. Nephrotic thrombotic risk may warrant a nephrology discussion about anticoagulation. For end-stage kidney disease, ACR favors transplantation over long-term dialysis when suitable; ongoing rheumatology follow-up remains necessary after dialysis or transplantation. Transplant timing does not require complete serologic remission if no other major organ involvement is present.
Adapt follow-up across life stages
In children, monitor growth and pubertal development and arrange a structured transition to adult care. In older adults, regularly reassess polypharmacy and doses as kidney function changes. Nephrology should consider preemptive transplantation when progressive kidney failure approaches an eGFR of 15, rather than assuming dialysis must come first.
Monitor response and toxicity
Quantify proteinuria at least every three months until complete response, then every three to six months during sustained response. Unexpected spot protein-to-creatinine results should be confirmed with a 24-hour collection, especially before changing therapy. Track kidney function, urine sediment, blood pressure, adherence, infection, marrow, and product-specific toxicity. Complement and anti-dsDNA are checked at clinic visits, no more often than monthly under the ACR good-practice statement; they supplement rather than replace renal outcomes. Voclosporin requires close eGFR, potassium, pressure, neurologic, QT, and interaction review.
Quick check
Checking for saved practice…
Lesson
Dose Voclosporin from the Kidney Trajectory
Voclosporin can help control adult active lupus nephritis, but a prescription must include a baseline, a monitoring calendar, and explicit action thresholds. A falling eGFR can reflect treatment toxicity as well as kidney disease.
- 23.7 mg twice daily
- Baseline eligibility
- Relative eGFR decline
- CYP3A interactions
- Administration
Apply renal reductions when eGFR is below 60 mL/min/1.73 m² and has fallen more than 20%.
A decline above 20% but below 30% reduces each BID dose by 7.9 mg; at least 30% requires discontinuation.
After discontinuation, recovery to at least 80% of baseline is required before considering restart at 7.9 mg twice daily.
Establish eligibility and the regimen
The labeled regimen uses voclosporin with mycophenolate mofetil and corticosteroids for adults with active lupus nephritis. Combination with cyclophosphamide is not recommended because safety and efficacy are unestablished. Starting eGFR at or below 45 mL/min/1.73 m² generally argues against use unless benefit outweighs risk. Do not initiate with blood pressure above 165/105 mmHg or a hypertensive emergency.
Prescribe and administer
Usual initiation is 23.7 mg twice daily: three intact 7.9 mg capsules per dose. Take consistently on an empty stomach near 12-hour intervals, never less than eight hours apart. Take a missed dose within four hours; beyond that, skip it and resume the schedule without doubling. Avoid grapefruit. Child-Pugh A or B uses 15.8 mg twice daily; Child-Pugh C is not recommended. If a specialist elects treatment despite severe baseline renal impairment, the starting dose is 15.8 mg twice daily.
Schedule surveillance
Check eGFR every two weeks during month one, every four weeks for the rest of year one, then quarterly. Check blood pressure every two weeks during month one and as clinically indicated thereafter. Also follow potassium, interacting drugs, infection, neurologic symptoms, and QT risk. Consider stopping if there is no therapeutic benefit by week 24.
Apply both renal conditions
Calculate decline as (baseline eGFR minus current eGFR) divided by baseline eGFR, multiplied by 100. If current eGFR is below 60 and the decline is more than 20% but less than 30%, lower each twice-daily dose by 7.9 mg. Recheck within two weeks; if decline remains above 20%, reduce each dose by another 7.9 mg. If current eGFR is below 60 and decline is at least 30%, discontinue and reassess within two weeks. A percentage alone does not satisfy this algorithm, although any unexpected decline warrants evaluation.
Reassess before restarting
After discontinuation for renal decline, consider restarting at 7.9 mg twice daily only when eGFR has recovered to at least 80% of baseline. After renal dose reductions, each measurement at or above 80% may support a 7.9 mg twice-daily increase, never above the starting dose. These are clinician decisions, not automatic patient self-adjustments. Blood pressure above 165/105 or hypertensive emergency during therapy requires discontinuation and antihypertensive treatment.
Work a renal example
Baseline eGFR 75 falling to 54 represents (75 minus 54)/75 × 100 = 28%. Both conditions are met: below 60 and a decline above 20% but below 30%. From 23.7 mg twice daily, reduce to 15.8 mg twice daily and recheck within two weeks. A fall from 75 to 50 is 33.3%, requiring discontinuation; recovery to at least 60 would meet the 80%-of-baseline threshold to consider low-dose restart.
Review inhibitors, inducers, and substrates
Strong CYP3A4 inhibitors such as clarithromycin are contraindicated. With a moderate inhibitor such as diltiazem or fluconazole, use 15.8 mg in the morning and 7.9 mg in the evening. Avoid strong or moderate CYP3A4 inducers. Voclosporin can increase P-glycoprotein substrate exposure and statin exposure through transporter inhibition; check the interacting product label and monitor toxicity. The voclosporin label limits simvastatin to 20 mg daily, or 40 mg only in patients who previously tolerated 80 mg for at least a year without muscle toxicity.
Protect against cumulative harm
Boxed warnings address serious infection and malignancy. Avoid live vaccines and reinforce sun protection. New seizure, confusion, severe headache, tremor, potassium elevation, serious hypersensitivity, or suspected pure red cell aplasia requires urgent evaluation. The label advises avoiding pregnancy because the formulation contains alcohol; MMF adds its own pregnancy-testing and contraception requirements. Current lactation labeling reports low measured milk exposure with insufficient infant-outcome data and calls for individualized benefit-risk assessment, rather than a categorical breastfeeding prohibition. EULAR 2024 advised avoiding voclosporin while breastfeeding because evidence was limited; distinguish that earlier guidance from the newer label data, which still do not establish infant safety.
Quick check
Checking for saved practice…
Lesson
Protect the Future Treatment Must Preserve
SLE outcomes reflect disease, treatment, infection, cardiovascular and bone risk, mental health, reproductive goals, and antiphospholipid antibodies. Prevention is part of immunosuppressive therapy, not an optional appendix.
- Vaccination
- Infection
- Cardiovascular risk
- Pregnancy planning
- Antiphospholipid antibodies
Coordinate non-live vaccines, selected medication timing, exposure screening, and an infection plan.
Reduce glucocorticoid burden and address pressure, lipids, tobacco, diabetes, activity, and screening.
Make medication transitions, antibody context, fertility, contraception, and pregnancy goals visible before conception.
Vaccinate with timing
Give indicated non-live vaccines and coordinate selected medication timing. Live-vaccine timing depends on the immunosuppressive regimen. Anifrolumab increases herpes zoster risk, making recombinant zoster vaccination especially relevant when indicated.
Reduce cumulative harm
Address tobacco, blood pressure, lipids, diabetes, bone health, malignancy screening, infection risk, mood, sleep, activity, and glucocorticoid exposure. Controlled inflammation does not erase preventable comorbidity.
Do not default to average-risk cervical screening
For a person with SLE who has a cervix, the 2025 ASCCP review recommends increased surveillance using the HIV cervical-screening framework, even without immunosuppressant treatment. This is a screening strategy, not an HIV diagnosis. Coordinate the schedule with gynecology using age, prior results, and treatment history. HPV vaccination does not remove the need for increased surveillance.
Plan pregnancy before exposure changes
Pregnancy outcomes improve when conception occurs during stable low activity on compatible therapy. Review mycophenolate, methotrexate, cyclophosphamide, renin-angiotensin drugs, anti-Ro and anti-La antibodies, thrombosis risk, contraception, fertility preservation, and pregnancy-compatible transitions before conception.
Keep disease controlled during pregnancy
Hydroxychloroquine is generally continued. EULAR 2024, published in 2025, also considers azathioprine, cyclosporine, and tacrolimus pregnancy compatible when appropriate; compatibility does not make them interchangeable for every organ. SMFM recommends low-dose aspirin from 12 weeks through delivery for SLE-related preeclampsia prevention, unless contraindicated. Arrange maternal disease monitoring and fetal growth surveillance with rheumatology and maternal-fetal medicine.
Separate maternal exposure from paternal counseling
Before attempting pregnancy, mycophenolate requires a compatible replacement and at least a six-week interval after stopping. Its US label requires pregnancy testing before initiation, again 8 to 10 days later, and during follow-up, plus acceptable contraception during treatment and for six weeks afterward. An oral contraceptive alone is insufficient under the label; use an approved additional barrier method or another acceptable option such as an IUD. Paternal advice differs: EULAR permits mycophenolate continuation when trying to conceive, while the July 2026 CellCept label recommends effective contraception during male treatment and for at least 90 days afterward. Explain this guideline-label difference in a documented specialist decision.
Distinguish pregnancy antibody risk states
Positive antiphospholipid antibodies without qualifying clinical APS generally call for low-dose aspirin in pregnancy, not automatic therapeutic anticoagulation. Obstetric APS without prior thrombosis calls for low-dose aspirin plus prophylactic heparin, usually LMWH. Thrombotic APS requires therapeutic heparin during pregnancy; ACR also recommends low-dose aspirin. Plan postpartum anticoagulation and delivery timing separately rather than stopping treatment automatically at birth.
Explain the fetal surveillance disagreement
Anti-Ro/SSA and anti-La/SSB can confer neonatal lupus and fetal heart-block risk. ACR 2020 conditionally supports serial fetal echocardiography from 16 to 18 weeks through week 26, with weekly studies after a previously affected infant. SMFM 2023 advises against routine serial PR-interval echocardiography outside trials and against routine steroids for antibody-associated fetal heart block because benefit is unproven. Present this disagreement explicitly and obtain an individualized maternal-fetal medicine and fetal-cardiology plan; do not treat either approach as universal consensus.
Use newer biologic evidence carefully
EULAR 2024 permits belimumab or rituximab when needed for maternal disease control, but reserves anifrolumab in pregnancy for situations where compatible alternatives cannot control disease because evidence is especially sparse. It considers biologic DMARDs compatible with breastfeeding, although evidence strength differs by drug and individual product labels can be more restrictive. Infant live-vaccine decisions after prenatal biologic exposure require pediatric review of the drug and exposure timing; non-live vaccines generally follow the usual schedule.
Keep reproductive advice product specific
Obinutuzumab labeling calls for effective contraception during treatment and for six months after the last dose, and advises against breastfeeding for the same interval because infant risk is uncertain. Belimumab labeling uses a benefit-risk assessment: when pregnancy prevention is warranted, contraception continues through treatment and at least four months afterward; lactation decisions weigh maternal need and breastfeeding benefits against potential infant effects. These are product-label positions, not interchangeable rules for every biologic. Coordinate any guideline-supported exception with the prescribing and maternal-fetal medicine teams rather than stopping disease control without a replacement plan.
Interpret antiphospholipid antibodies in context
Persistent high-risk antibodies and a thrombotic or obstetric history can define antiphospholipid syndrome and change anticoagulation, estrogen, pregnancy, and procedural decisions. An isolated positive result is not automatically APS.
Quick check
Checking for saved practice…
Lesson
Make the Lupus Timeline Authoritative
Long-term SLE care depends on a visible record of organ history, activity, damage, therapy exposure, adherence, toxicity, screening, vaccines, reproductive planning, access, and the next decision.
- Remission
- Immunosuppressive taper
- Flare plan
- Handoff
- Access
Capture prior responses, toxicities, access failures, damage, and the reason for each change.
Document active exposure, disease activity, organ function, safety monitoring, and current holds.
State the target, taper or escalation trigger, urgent flare plan, and responsible clinician.
Taper only after durable control
For nonrenal SLE, after three to five years of sustained remission or low disease activity, a cautious immunosuppressive taper toward discontinuation can be considered. Hydroxychloroquine is generally continued. Change one element, preserve monitoring, and define rescue criteria. For nephritis, use the renal response and total-treatment framework in the kidney lesson rather than substituting this nonrenal taper timeline.
Write the flare plan before the flare
Name early symptoms, urgent renal, neurologic, cardiopulmonary, hematologic, thrombotic, and infectious signals, the contact route, required tests, and who can change therapy. Leftover high-dose steroids are not a substitute for assessment.
Build the handoff
Document every organ ever involved, last disease-activity and damage assessment, exact weekly or infusion timing, current holds, previous failures and toxicities, kidney and blood trends, vaccine status, reproductive plan, and restart ownership.
Design for actual access
Transportation, infusion distance, insurance, language, medication supply, monitoring burden, and specialist availability shape whether an evidence-based plan reaches the patient. Choose a sustainable route and treat access failure as a system problem, not a character judgment.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 113 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- SMFM Consult Series 64. Systemic lupus erythematosus in pregnancy, 2023.
- EULAR. Antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update, published 2025.
- Genentech. CellCept prescribing information, revised July 2026.
- DailyMed. Azathioprine prescribing information: laboratory monitoring and xanthine oxidase interactions.
- DailyMed. Febuxostat prescribing information: thiopurine contraindication.
- Moscicki AB, et al. Updated review for cervical cancer screening in immunosuppressed women without HIV infection, 2025.
- DailyMed. Methimazole: lupus-like syndrome and vasculitis warnings.
- DailyMed. Methyldopa: lupus-like syndrome adverse reaction.
- DailyMed. Terbinafine: precipitation or exacerbation of lupus.
- DailyMed. Hydralazine: lupus syndrome including glomerulonephritis.
- American Academy of Ophthalmology. Hydroxychloroquine retinopathy screening, 2025 revision.
- American College of Rheumatology. 2025 Guideline for the Treatment of Systemic Lupus Erythematosus.
- American College of Rheumatology. 2024 Lupus Nephritis Guideline, full manuscript published 2025.
- American College of Rheumatology. 2019 EULAR and ACR Classification Criteria for Systemic Lupus Erythematosus.
- American College of Rheumatology. 2020 Reproductive Health Guideline.
- Bass AR, et al. 2022 ACR Guideline for Vaccinations in Rheumatic and Musculoskeletal Diseases.
- DailyMed. Hydroxychloroquine Sulfate Tablets Prescribing Information.
- DailyMed. Benlysta Belimumab Prescribing Information.
- DailyMed. Saphnelo Anifrolumab Prescribing Information.
- DailyMed. Lupkynis Voclosporin Prescribing Information.
- DailyMed. Gazyva Obinutuzumab Prescribing Information.
- American College of Rheumatology. Lupus Patient Information.